13.43 -0.29 (-2.11%)

New 52W High in past week

54,182 XNAS Volume

XNAS 28 Mar, 2025 5:30 PM (EDT)

Board Meeting
The next board meeting for Benitec Biopharma Inc is on 31 Mar 2025 for the purpose of Benitec Biopharma Inc Annual Report for 2024 See details


Insider Trading disclosures for Benitec Biopharma Inc

The latest disclosure was made by J. Kevin Buchi in Benitec Biopharma Inc where a trade of 103,626 Common Stock done was reported to US exchanges on March 12, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
J. Kevin Buchi Director Gift of securities by or to the insider at price $ 0.00 per share. 12 Mar 2025 103,626 103,626 - 0 Common Stock
J. Kevin Buchi Director Gift of securities by or to the insider at price $ 0.00 per share. 12 Mar 2025 103,626 284 - 0 Common Stock
J. Kevin Buchi Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 27 Feb 2025 51,813 0 - - Common Warrants (right to buy)
J. Kevin Buchi Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.86 per share. 27 Feb 2025 51,813 103,910 - 3.9 199,998 Common Stock
Kishan Mehta Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 Dec 2024 35,000 35,000 - - Options (right to buy)
Jerel A. Banks Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 Dec 2024 2,310,000 2,310,000 - - Options (right to buy)
Megan Boston Director, Executive Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 Dec 2024 720,000 720,000 - - Options (right to buy)
Peter Francis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 Dec 2024 35,000 35,000 - - Options (right to buy)
Edward F. Smith Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 Dec 2024 35,000 35,000 - - Options (right to buy)
J. Kevin Buchi Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 Dec 2024 35,000 35,000 - - Options (right to buy)
Jerel A. Banks Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 06 Mar 2024 466,554 466,554 - - Options (right to buy)
Megan Boston Director, Executive Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 06 Mar 2024 200,004 200,004 - - Options (right to buy)
Edward Smith F. Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 06 Dec 2023 35,000 35,000 - - Options (right to buy)
Buchi Kevin J. Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 06 Dec 2023 35,000 35,000 - - Options (right to buy)
Peter Francis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 06 Dec 2023 35,000 35,000 - - Options (right to buy)
Megan Boston Director, Executive Director Purchase of securities on an exchange or from another person at price $ 0.00 per share. 11 Aug 2023 25,907 25,907 - - Common Stock
Megan Boston Director, Executive Director Purchase of securities on an exchange or from another person at price $ 0.00 per share. 11 Aug 2023 25,907 25,907 - - Common Warrants (right to buy)
J. Kevin Buchi Director Purchase of securities on an exchange or from another person at price $ 0.00 per share. 11 Aug 2023 51,813 51,813 - - Common Warrants (right to buy)
J. Kevin Buchi Director Purchase of securities on an exchange or from another person at price $ 0.00 per share. 11 Aug 2023 51,813 52,097 - - Common Stock
Jerel A. Banks Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Jun 2023 356,900 356,900 - - Options (right to buy)
Megan Boston Director, Executive Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Jun 2023 153,000 153,000 - - Options (right to buy)
Edward F. Smith Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 Dec 2020 23,601 23,601 - - Options (right to buy)
Megan Boston Director, Executive Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 Dec 2020 142,172 142,172 - - Options (right to buy)
J. Kevin Buchi Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 Dec 2020 23,601 23,601 - - Options (right to buy)
Jerel A. Banks Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 Dec 2020 284,345 284,345 - - Options (right to buy)
Peter Francis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 09 Dec 2020 23,601 23,601 - - Options (right to buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures